Endocrine/metabolic https://www.bioworld.com/rss en-us Pfizer discloses new dual calcitonin/amylin receptor agonists http://www.bioworld.com/articles/731308 Thu, 14 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731308-pfizer-discloses-new-dual-calcitonin-amylin-receptor-agonists In the mix post-Ventyx, more NLRP3s to seize? Nature that delved into mechanisms that rev up the NLRP3 inflammasome.]]> http://www.bioworld.com/articles/731061 Wed, 13 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731061-in-the-mix-post-ventyx-more-nlrp3s-to-seize NLRP3 inflammasome Nvision secures $55 million, with backing from Abbott BioWorld that the funds are extremely important as the company is scaling the Polaris systems to many more sites worldwide, which is a capital intensive process.]]> http://www.bioworld.com/articles/731059 Wed, 13 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731059-nvision-secures-55-million-with-backing-from-abbott Nvision's Polaris system Polaris quantum-enhanced sensing platform. Credit: Nvision Imaging Technologies GmbH Up to BAT in PSC, Mirum base case proven with phase IIb http://www.bioworld.com/articles/730831 Wed, 13 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730831-up-to-bat-in-psc-mirum-base-case-proven-with-phase-iib Liver disease GSK licenses siRNA asset in $1B deal for Siranbio http://www.bioworld.com/articles/731226 Tue, 12 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731226-gsk-licenses-sirna-asset-in-1b-deal-for-siranbio Illustration of siRNA structure Metis Techbio, Impact Tx cleared for Hong Kong IPOs http://www.bioworld.com/articles/731048 Tue, 12 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731048-metis-techbio-impact-tx-cleared-for-hong-kong-ipos Businessman and IPO virtual screen Fractyl Health’s RJVA-001 cleared to enter clinic in Netherlands http://www.bioworld.com/articles/731012 Tue, 12 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731012-fractyl-healths-rjva-001-cleared-to-enter-clinic-in-netherlands Beta cells β cell. Credit: Melton laboratory, Harvard University MBX highlights early data for monthly obesity drug MBX-4291 http://www.bioworld.com/articles/731031 Mon, 11 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731031-mbx-highlights-early-data-for-monthly-obesity-drug-mbx-4291 Injector pen and spiraling measuring tape FDA slowdown on Tzield sBLA underlines CNPV questions http://www.bioworld.com/articles/730970 Thu, 07 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730970-fda-slowdown-on-tzield-sbla-underlines-cnpv-questions FDA logo on textured paper Credit: Araki Illustrations - stock.adobe.com Ascletis Pharma divulges new GIPR and GLP-1R agonists http://www.bioworld.com/articles/730943 Thu, 07 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730943-ascletis-pharma-divulges-new-gipr-and-glp-1r-agonists GSK licenses siRNA asset in $1B deal for Siranbio http://www.bioworld.com/articles/730864 Wed, 06 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730864-gsk-licenses-sirna-asset-in-1b-deal-for-siranbio Illustration of siRNA structure Apelin receptor agonists disclosed in Zhuhai United Laboratories patent http://www.bioworld.com/articles/730917 Wed, 06 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730917-apelin-receptor-agonists-disclosed-in-zhuhai-united-laboratories-patent MYO technology enables DNA delivery of incretin agonists for durable weight loss http://www.bioworld.com/articles/730903 Wed, 06 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730903-myo-technology-enables-dna-delivery-of-incretin-agonists-for-durable-weight-loss Bio Korea 2026 kicks off with spotlight on oligonucleotides http://www.bioworld.com/articles/730927 Tue, 05 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730927-bio-korea-2026-kicks-off-with-spotlight-on-oligonucleotides AI generated image for researcher developing antisense oligonucleotides Madrigal expands MASH pipeline in potential $1B Arrowhead deal http://www.bioworld.com/articles/730851 Tue, 05 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730851-madrigal-expands-mash-pipeline-in-potential-1b-arrowhead-deal Liver and DNA Quintuple GLP-1-GIP-PPAR agonist for obesity and diabetes control http://www.bioworld.com/articles/730790 Thu, 30 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730790-quintuple-glp-1gipppar-agonist-for-obesity-and-diabetes-control Glucagon-like peptide-1 receptor (GLP-1R) complex Glucagon-like peptide-1 receptor (GLP-1R) complex, representing the molecular target for GLP-1 agonists. Detailed view of the binding site with small-molecule agonist. Bio Korea 2026 kicks off with spotlight on oligonucleotides http://www.bioworld.com/articles/730686 Wed, 29 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730686-bio-korea-2026-kicks-off-with-spotlight-on-oligonucleotides AI generated image for researcher developing antisense oligonucleotides Pfizer identifies new GIPR antagonists http://www.bioworld.com/articles/730732 Tue, 28 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730732-pfizer-identifies-new-gipr-antagonists Pfizer patents describe GIPR antagonists http://www.bioworld.com/articles/730711 Mon, 27 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730711-pfizer-patents-describe-gipr-antagonists Crinetics Pharmaceuticals patents TSHR antagonists http://www.bioworld.com/articles/730708 Mon, 27 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730708-crinetics-pharmaceuticals-patents-tshr-antagonists Single-gene therapy for LSDs with modified lysosomal enzyme shows preclinical efficacy http://www.bioworld.com/articles/730698 Mon, 27 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730698-single-gene-therapy-for-lsds-with-modified-lysosomal-enzyme-shows-preclinical-efficacy Neurons Suzhou Spring-Sea Bio-Pharmaceuticals discloses new GLP-1R/GCGR/GIPR agonists http://www.bioworld.com/articles/730656 Fri, 24 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730656-suzhou-spring-sea-bio-pharmaceuticals-discloses-new-glp-1r-gcgr-gipr-agonists CMS to Bridge coverage for obesity drugs as BALANCE teeters http://www.bioworld.com/articles/730497 Wed, 22 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730497-cms-to-bridge-coverage-for-obesity-drugs-as-balance-teeters Generic injection pens Hinova Pharmaceuticals presents new prodrugs of orforglipron http://www.bioworld.com/articles/730567 Wed, 22 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730567-hinova-pharmaceuticals-presents-new-prodrugs-of-orforglipron Insilico Medicine divulges new NLRP3 inflammasome inhibitors http://www.bioworld.com/articles/730550 Tue, 21 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730550-insilico-medicine-divulges-new-nlrp3-inflammasome-inhibitors Tokyo universities describe new compounds for dyslipidemia http://www.bioworld.com/articles/730526 Mon, 20 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730526-tokyo-universities-describe-new-compounds-for-dyslipidemia Obesity-focused Kailera goes for US biopharma record with $625M IPO BioWorld data.]]> http://www.bioworld.com/articles/730403 Fri, 17 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730403-obesity-focused-kailera-goes-for-us-biopharma-record-with-625m-ipo Gold IPO with chart Ascletis Pharma discovers new THR-β agonists http://www.bioworld.com/articles/730463 Fri, 17 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730463-ascletis-pharma-discovers-new-thr-agonists HYJ-2 arises as candidate for uric acid disorders http://www.bioworld.com/articles/730451 Fri, 17 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730451-hyj-2-arises-as-candidate-for-uric-acid-disorders 3D rendering of uric acid molecules in the bloodstream Sex differences shape gene activity across the human brain http://www.bioworld.com/articles/730447 Fri, 17 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730447-sex-differences-shape-gene-activity-across-the-human-brain Brain and DNA